ARVN stock news
This page provides real-time market news, earnings updates, and company announcements related to Arvinas, Inc. (ARVN).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-06-27 06:05 EST
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
Finviz2026-02-12 12:06:42
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Finviz2026-02-17 12:03:43
Arvinas to Participate in Upcoming Investor Conferences
Finviz2026-02-23 12:03:46
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-02-24 12:03:58
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
Finviz2026-03-02 08:00:49
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Finviz2026-03-11 11:03:53
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
Finviz2026-03-18 11:03:56
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026.
老虎证券2026-06-16 20:48:11
According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a tiered royalty structure.
老虎证券2026-06-16 20:48:22
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
Finviz2026-03-02 08:00:49
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Finviz2026-03-11 11:03:53
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
Finviz2026-03-18 11:03:56
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026.
老虎证券2026-06-16 20:48:11
According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a tiered royalty structure.
老虎证券2026-06-16 20:48:22
ARVN stock chart
ARVN stock detailsARVN stock price change
On the last trading day, ARVN stock closed at 8.21 USD, with a price change of 2.30% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more